Autres langues ARS Pharmaceuticals, Inc.

Actions

SPRY

US82835W1080

Recherche biotechnologique et médicale

Marché Fermé - 22:00:00 11/09/2026 Varia. 5j. Varia. 1 janv.
4,760 USD -5,93% Graphique intraday de ARS Pharmaceuticals, Inc. -15,30% -59,14%

Autres langues

01/09 ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
13/08 ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises
13/08 ARS Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
13/08 ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
03/08 ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results
17/07 Ars Pharmaceuticals, Inc. Announces Management Changes, Effective July 15, 2026
07/07 ARS Pharmaceuticals Announces CEO Succession
07/07 ARS Pharmaceuticals, Inc. Announces Appointment of Donn Casale as Director, Effective July 7, 2026
07/07 ARS Pharmaceuticals, Inc. Announces CEO Changes
01/07 SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud
29/06 ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Defensive Index
29/06 ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Growth-Defensive Index
25/06 MÄRKTE USA/Apple-Preiserhöhungen dämpfen Micron-Euphorie
25/06 MÄRKTE USA/Apple-Preiserhöhungen dämpfen Micron-Euphorie
25/06 MÄRKTE USA/Uneinheitlich - Preiserhöhungen belasten Apple
25/06 MÄRKTE USA/Uneinheitlich - Micron-Zahlen und Inflationsdaten lindern Nervosität
25/06 MÄRKTE USA/Micron-Zahlen dürften für gute Börsenstimmung sorgen
25/06 Top Premarket Decliners
25/06 ARS Pharmaceuticals Updates Neffy Coverage Outlook, Cuts 2026 Costs
24/06 ARS Pharmaceuticals Provides Commercial and Financial Updates
04/06 Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
15/05 ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
15/05 ARS Pharmaceuticals Q1 Loss Widens, Revenue Rises; Shares Up Pre-Bell
15/05 Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Loss $0.61 a Share, vs. FactSet Est of $0.49 Loss
15/05 Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q1 Revenue $22.7M, vs. FactSet Est of $22.2M
Aucun résultat pour cette recherche
-40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT